Search Results for "folic acid"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for folic acid. Results 11 to 20 of 26 total matches.
Lowering Plasma Homocysteine
The Medical Letter on Drugs and Therapeutics • Oct 27, 2003 (Issue 1168)
: www.medicalletter.org
THE MEDICAL LETTER · A NONPROFIT ORGANIZATION
Folic acid Atherosclerosis risk Coronary heart ...
High plasma homocysteine concentrations, like high cholesterol, have been associated with an increased risk of cardiovascular disease and death (O Nygσrd et al, N Engl J Med 1997; 337:230; RS Vasan et al, JAMA 2003; 289:1251). In one meta-analysis, 25% lower plasma homocysteine concentrations were associated with 11% less coronary heart disease and 19% less stroke (Homocysteine Studies Collaboration, JAMA 2002; 288:2015). Should we be trying to lower serum homocysteine concentrations in our patients?
Direct-to-consumer Advertisements For Glucophage XR
The Medical Letter on Drugs and Therapeutics • Mar 19, 2001 (Issue 1100)
absorption of vitamin B
12
and folic acid,
causing a deficiency of these vitamins.
WHAT’S DIFFERENT ...
Full-page newspaper advertisements addressed to patients with type 2 diabetes are promoting the convenience of "NEW once-a-day Glucophage XR (metformin HCl extended-release tablets),"and offering a coupon for a free 30-day supply in the month of March.
Prevention of Pneumocystis Carinii Pneumonia
The Medical Letter on Drugs and Therapeutics • Oct 07, 1988 (Issue 776)
, interferes with folic acid synthesis, frequently
causes anemia and methemoglobinemia.
Aerosolized ...
Pneumocystis carinii pneumonia (PCP) is a common cause of death in patients with acquired immune deficiency syndrome (AIDS). PCP is the first serious opportunistic infection in more than 60% of patients with AIDS, and about 80% of AIDS patients develop PCP at least once (AE Glatt et al, N Engl J Med, 318:1439, June 2, 1988). Many studies using drugs to prevent PCP in patients with AIDS have recently been reported.
Metformin for Non-Insulin-Dependent Diabetes Mellitus
The Medical Letter on Drugs and Therapeutics • May 12, 1995 (Issue 948)
itself can decrease
absorption of vitamin B
12
and folic acid, causing a deficiency of these vitamins ...
Metformin (Glucophage - Bristol-Myers Squibb), a hypoglycemic agent, was recently marketed in the USA for oral treatment of patients with non-insulin-dependent diabetes mellitus (NIDDM) not adequately controlled by diet alone. Previously marketed in more than ninety countries, including Canada, metformin (dimethylbiguanide) is chemically related to phenformin (phenylethylbiguanide), which was withdrawn from the US market in 1976 because it caused a high incidence of lactic acidosis. In approving metformin, the US Food and Drug Administration stipulated that a post-marketing controlled...
Expanded Table: Some Drugs for Inflammatory Bowel Disease (online only)
The Medical Letter on Drugs and Therapeutics • Jul 10, 2023 (Issue 1680)
of supplements containing folic acid (1-4 mg daily) or folinic acid (2.5-10 mg weekly 24 hours after ...
View the Table: Some Drugs for Inflammatory Bowel Disease
Med Lett Drugs Ther. 2023 Jul 10;65(1680):e115-9 doi:10.58347/tml.2023.1680d | Show Introduction Hide Introduction
Valproate and Other Anticonvulsants For Psychiatric Disorders
The Medical Letter on Drugs and Therapeutics • Dec 11, 2000 (Issue 1094)
and neural tube defects. Folic acid antagonism has been implicated (S Hernandez-Diaz et al, N Engl J Med ...
Anticonvulsants are now widely used for treatment of psychiatric illnesses, particularly bipolar disorder. Lithium is the standard drug for treatment of bipolar disorder, but it can cause severe toxicity, serum concentrations must be monitored, and it is not effective in some patients.
Drugs for Rheumatoid Arthritis
The Medical Letter on Drugs and Therapeutics • Nov 15, 2021 (Issue 1637)
to rapidly dividing cells; periodic CBC monitoring
and supplementation with folic acid or folinic
acid ...
Rheumatoid arthritis (RA) is prevalent in 0.5% of
adults in the US; it is about 2.5 times more common
in women than in men. Guidelines for treatment
of RA from the American College of Rheumatology
were recently updated. The goal of treatment is to
minimize disease activity and prevent irreversible
joint damage.
Eculizumab (Soliris) for Paroxysmal Nocturnal Hemoglobinuria
The Medical Letter on Drugs and Therapeutics • Sep 24, 2007 (Issue 1270)
OTHER TREATMENTS FOR PNH — Supportive
care for patients with PNH includes hydration, anticoagulation, folic acid ...
Eculizumab (Soliris - Alexion) has been approved by the FDA for reduction of hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH), a rare form of hemolytic anemia. A recombinant humanized monoclonal antibody, eculizumab is the first drug to be marketed for this indication.
Comparison Table: Some Drugs for Gout (online only)
The Medical Letter on Drugs and Therapeutics • Oct 30, 2023 (Issue 1688)
to
methotrexate 15 mg PO once
weekly and folic acid or folinic
acid, started at least 4 weeks
before starting ...
View the Comparison Table: Some Drugs for Gout
Med Lett Drugs Ther. 2023 Oct 30;65(1688):e176-9 doi:10.58347/tml.2023.1688c | Show Introduction Hide Introduction
Drugs for Epilepsy
The Medical Letter on Drugs and Therapeutics • Aug 05, 2024 (Issue 1708)
. Serum folic acid, thyroxine, and vitamin K concentrations may decrease with long-term therapy ...
When used for the appropriate seizure type,
antiseizure medications (ASMs) are roughly
equivalent in efficacy. In addition to the seizure type,
the choice of drug is usually based on factors such
as ease of use, spectrum of activity, adverse effects,
interactions with other drugs, presence of comorbid
conditions, suitability for elderly persons and those
with childbearing potential, and cost. Treatment
should begin with a single drug, increasing the
dosage gradually until seizures are controlled or
adverse effects become unacceptable. If seizures
persist, expert clinicians generally...
Med Lett Drugs Ther. 2024 Aug 5;66(1708):121-8 doi:10.58347/tml.2024.1708a | Show Introduction Hide Introduction